No Data
Outlook Therapeutics Issues Convertible Note to Avondale
Outlook Therapeutics Files to Sell 7.07M Shares of Common Stock for Holders
Outlook Therapeutics Shares Are Trading Higher After the Company Re-submitted Its Biologics License Application for ONS-5010 in Wet AMD to the FDA.
Outlook Therapeutics Re-Submits Its Biologics License Application For ONS-5010 In Wet AMD To The FDA
Express News | Outlook Therapeutics Inc - FDA Decision Expected Within Six Months
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
